This inventor holds 4 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: Epigenomics Ag. Active years: 2008-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008-2018
Title: The Innovations of Peter Adorjan
Introduction
Peter Adorjan is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of molecular biology, particularly in the analysis of cell proliferative disorders. With a total of 4 patents to his name, Adorjan's work has the potential to impact cancer diagnostics and treatment.
Latest Patents
Among his latest patents is a method and nucleic acids for the analysis of colon cell proliferative disorders. This invention provides methods and nucleic acids for detecting, differentiating, or distinguishing between colon cell proliferative disorders by analyzing specific genes such as Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Additionally, he has developed novel nucleic acid sequences that are useful for the specific analysis of these genes, along with methods, assays, and kits for their application. Another significant patent relates to methods for the prognosis of breast cancer. This invention involves modified and genomic sequences, oligonucleotides, and PNA-oligomers for detecting the cytosine methylation state of genomic DNA. It also includes a method for predicting disease-free survival and response to endocrine treatment in subjects with cell proliferative disorders of breast tissues.
Career Highlights
Peter Adorjan is currently associated with Epigenomics AG, a company focused on developing innovative cancer diagnostics. His work at Epigenomics AG has allowed him to further his research and contribute to advancements in the field of epigenetics.
Collaborations
Adorjan has collaborated with several professionals in his field, including Sabine Maier and Ralf Lesche. These collaborations have likely enhanced the scope and impact of his research.
Conclusion
Peter Adorjan's contributions to the field of molecular biology and cancer diagnostics are noteworthy. His innovative patents and work at Epigenomics AG demonstrate his commitment to advancing medical science. His research has the potential to improve the diagnosis and treatment of serious health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile